|
KMID : 1146920220520040443
|
|
Journal of Pharmaceutical Investigation
2022 Volume.52 No. 4 p.443 ~ p.451
|
|
|
The combined effects of telmisartan and ramipril on hypertension and cardiovascular injury
|
|
Lee Do-Hyung
Kim Min-Tae
Lee Hyung-Won
Han Joo-Hui
Myung Chang-Seon
|
|
|
Abstract
|
|
|
Purpose: More than half of hypertensive patients receive combination therapy with two or more drugs. For combination therapy with antihypertensive drugs, it is recommended to use complementary drugs with different mechanisms. In this study, the effects of combination therapy with telmisartan (an angiotensin II receptor type 1 blocker) and ramipril (an angiotensin-converting enzyme inhibitor) on blood pressure control and cardiovascular protection were verified.
Methods: The systolic blood pressure (SBP), mean arterial pressure (MAP), and heart rate of spontaneously hypertensive rats (SHRs) were measured using a telemetry system. The protective effect of the drug combination against cardiovascular injury was determined by examining ligation-induced myocardial ischemia/reperfusion in SHRs and cuff-induced neointimal formation in C57BL/6 mice.
Results: The combination therapy with telmisartan and ramipril significantly decreased SBP and MAP. In addition, the combination therapy significantly increased the expression of endothelial nitric oxide synthase and inhibited the proliferation of vascular smooth muscle cells by inhibiting DNA synthesis at the cuff-induced vascular injury site.
Conclusion: The results of this study suggest that combination therapy with telmisartan and ramipril is an effective strategy for the treatment of hypertension and complications of hypertensive disorders.
|
|
|
KEYWORD
|
|
|
Telmisartan, Ramipril, Combination therapy, Antihypertension, Cardiovascular protection
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|